Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $8.9100 (6.07%) ($8.4000 - $9.6200) on Tue. Mar. 3, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.68% (three month average) | RSI | 41 | Latest Price | $8.9100(6.07%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -0.5% a day on average for past five trading days. | Weekly Trend | AUTL declines -8.8% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) DRIV(16%) EWI(16%) IBB(15%) IFRA(15%) XLB(15%) | Factors Impacting AUTL price | AUTL will decline at least -2.34% in a week (0% probabilities). VXX(-9%) VIXM(-8%) TLT(-5%) SHY(-2%) BWX(-1%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.34% (StdDev 4.68%) | Hourly BBV | 0 () | Intraday Trend | 3% | | | |
|
1 - 5 Day Possible Target | $-5.43(-160.94%) | Resistance Level | $9.72 | 5 Day Moving Average | $8.68(2.65%) | 10 Day Moving Average | $9.33(-4.5%) | 20 Day Moving Average | $9.72(-8.33%) | To recent high | -45% | To recent low | 8.9% | Market Cap | $466m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |